Search PubMed⌕ Search

Biomedical subjects

A Fasoli

Publications and source records attributed to A Fasoli.

At least 73 records · Page 4Linked to original sources
PubMed1984

Long-term effects of fenofibrate on serum lipids and on lipoprotein cholesterol in type II hyperlipoproteinemic patients.

Twenty two patients with primary type II hyperlipoproteinemia (13 phenotype IIa and 9 phenotype IIb) were treated with fenofibrate 300 mg a day for 4-12 months. Serum total cholesterol decreased, on the average, by 22 per cent and LDL cholesterol by 24 per cent. In the patients with familial hypercholesterolemia, total cholesterol decreased by 28 per cent and LDL cholesterol by 31 per cent. One patient with homozygous familial hypercholesterolemia showed the greatest fall of total and LDL cholesterol (44 and 48 per cent respectively) and this was accompanied by a nearly complete disappearance of xanthelasmas and xanthomas.

Adult↗
PubMed1984

Effect of D-glucitol-hexanicotinate on platelet aggregability in patients with coronary heart disease.

D-glucitol-hexanicotinate (sorbinicate) was administered at a daily dose of 1.6 mg to 16 male patients who had survived myocardial infarction. Platelet aggregation induced by collagen (5 micrograms/ml), by ADP (2, 1.2, 0.8, and 0.4 X 10(-6)M), and by epinephrine (1 and 0.5 X 10(-6)M) was significantly decreased after 3 months of therapy. In a group of 13 comparable patients, who did not receive sorbinicate, platelet aggregation induced by ADP (1.2, 0.8, and 0.4 X 10(-6)M) and by epinephrine (1 X 10(-5)M and 1 X 10(-6)M) was significantly increased 3 months after entry into the study. Sorbinicate has effective lipid-lowering activity; the combination of hypolipidemic and anti-aggregating properties may prove important in primary and secondary prevention of atherosclerotic disease.

Adenosine Diphosphate↗
PubMed1983

Anionic glycoproteins and their hexosamine content in neoplastic patients: relationships with the clinical stage and the course of the disease.

In 40 healthy subjects, in 47 non-cancer patients, and in 142 cancer patients, perchloric acid soluble glycoproteins (PASG) and hexosamines were determined to investigate their tumor specificity and correlation with the tumor mass. Cancer patients were divided into three subgroups: CI, no evidence of cancer (after radical surgery); CII, locoregional disease; CIII, widespread metastatic disease. There was no statistically significant difference in PASG among normals, non-cancer and CI patients; hexosamines in non-cancer and in CI patients were higher (P less than 0.002) than in normals; both PASG and hexosamines were significantly higher in CII and CIII patients than in normals (P less than 0.001). In the CI group, 62% of patients who relapsed within 10 months after surgery had high hexosamine values, whereas 69% of patients who did not relapse showed normal levels (P less than 0.05). PASG and hexosamines significantly increased with cancer progression and decreased when objective response to treatment was achieved. They are not tumor specific, but seem to be related to the tumor burden; hexosamines seem to have some prognostic value.

Adult↗
PubMed1983

[Serum lipoproteins and coronary disease in diabetes. Changes in the lipoprotein pattern in relation to the type of antidiabetic therapy].

One hundred and fifty seven maturity-onset diabetics (77 males and 80 females) with coronary heart disease (CHD) were compared with 130 non-CHD diabetic patients (62 males and 68 females) of the same age-range. Integrated mean blood pressure, duration of diabetes, serum triglycerides, beta and prebeta-lipoproteins were significantly higher and alpha lipoproteins significantly lower in CHD than in non-CHD patients. Alpha lipoproteins, duration of diabetes and beta lipoproteins were the variables of highest weight in discriminating CHD from non-CHD patients. Alpha lipoprotein had a greater discriminating power than beta lipoprotein in man, while in women the opposite occurred. In patients on insulin and on sulfonylurea therapy, both with and without CHD, the concentration of alpha lipoproteins, but not of other lipoproteins, was higher than in the corresponding subgroups of the diet-treated patients. However, within each treatment group, patients with CHD had lower alpha lipoproteins.

Blood Pressure↗
PubMed1983

Effects of intravenous high doses of ketoprofen on blood clotting, bleeding time and platelet aggregation in man.

The effect of ketoprofen (Orudis, Farmitalia) on ADP, epinephrine (EPI) and collagen (COLL) induced platelet aggregation (PlA), simplate bleeding time (SBT), partial thromboplastin time (PTT) and per cent prothrombin activity (PrA) was studied in eleven patients, four males and seven females (median age 59 years) with rheumatoid arthritis (six cases), cancer (four cases) and osteoarthrosis (one case). Tests were performed before and 1, 8 and 24 hours after a single intravenous dose (600 mg) of ketoprofen and on Days 4 and 8 during a 7-day treatment (200 mg i.v. every 8 hours) and 1 day after withdrawal of the drug. PTT and PrA were not affected by the drug. Bleeding time was not significantly modified by the acute treatment, but was prolonged during the subacute course, though it was not different from baseline values at the end of the trial. Significant reduction of platelet aggregation was seen in both acute and subacute conditions with complete or almost complete recovery 36 hours after the last dose. It is concluded that ketoprofen affects platelets with readily reversible inhibition of in vitro aggregation and a slight increase of bleeding time.

Aged↗
PubMed1981

Increase in lipolysis and decrease in plasma-heparin lipoprotein lipase activity and alpha 1 lipoprotein level after aminophylline in man.

Intravenous aminophylline 0.48 g produced a sharp increase in plasma free fatty acids. After three days of treatment with aminophylline 0.96 g/day i.v., plasma post-heparin lipoprotein lipase was significantly reduced, and post-heparin hepatic triglyceridase remained unchanged. alpha 1 lipoprotein was reduced by treatment, in parallel with lipoprotein lipase, while other lipoprotein fractions, serum cholesterol and triglycerides were unaffected.

Adult↗
PubMed1981

Influence of two non-steroidal anti-inflammatory drugs on lipolysis and on plasma post-heparin lipoprotein lipase activity in normal man.

Indomethacin 50 mg i.v. or p.o. and diclofenac sodium 50 mg p.o. produced a prompt and significant increase in plasma free fatty acid concentration. In 10 subjects who took indomethacin 150 mg/d p.o. for 3 days, plasma post-heparin lipoprotein lipase activity was also significantly increased. The same effect occurred in 9 subjects treated for 3 days with diclofenac sodium 50 mg t.d.s. Since both indomethacin and diclofenac sodium are potent inhibitors of prostaglandin synthetase, these findings are consistent with the hypothesis tht prostaglandins are involved in the feed-back regulation of lipolysis, and mediate the inhibitory effect of lipolysis on lipoprotein lipase activity.

Adult↗
PubMed1981

Effects of acetylsalicylic acid on plasma lipids and on post-heparin lipase activities.

Acetylsalicylic acid (ASA) was administered orally at the dose of 3 g a day for 2 days to healthy subjects. Plasma free fatty acids, serum triglycerides and prebetalipoproteins were significantly decreased, while cholesterol, beta and alpha 1 lipoproteins did not change. The two fractions (protamine-resistant and protamine-inactivated) of plasma post-heparin lipoprotein lipase activity (PHLA) significantly fell after ASA. PHLA diminution was reproduced by direct addition of ASA or sodium salicylate or of plasma from individuals under treatment with ASA to post-heparin plasma of untreated subjects and is, therefore, explained by a direct inactivation. The inhibition of PHLA was not followed by a significant impairment of the removal of circulating triglycerides.

Adult↗
PubMed1980

Evidence of an effect of inhaled disodium cromoglycate on lipid metabolism in man: enhanced lipolysis and decreased plasma post-heparin lipase activities.

Inhalation of therapeutic doses of disodium cromoglycate (DSCG) was followed by a prompt increase of plasma free fatty acids (FFA). After treatment with DSCG for 3 days both hepatic and non-hepatic (lipoprotein lipase sensu strictiori) plasma post-heparin lipoprotein lipase activities were significantly depressed. No significant change was induced on serum lipids and lipoproteins, nor on the fat tolerance curve, though a trend to an elevation of this last parameter was noted. Our results show that the inhalation of DSCG produces systemic metabolic effects, being in accord with the view that this drug raises intracellular cyclic adenosine monophosphate. Furthermore, they support the contention that lipoprotein lipase activity is controlled by intracellular concentration of FFA and/or cyclic adenosine monophosphate.

Adipose Tissue↗
PubMed1978

An evaluation of quantitative agarose-gel electrophoresis of serum lipoproteins.

The method of Hatch et al. (Hatch, F.T., Lindgren, F.T., Adamson, G.L., Jensen, L.C. and Wong, A.W. (1973) J. Lab. Clin. Med. 81, 946-960) of quantitative determination of serum lipoproteins has been compared with preparative ultracentrifugation and chemical analysis of the lipoprotein fractions and a good concordance was demonstrated. The replacement of the coefficients proposed by Hatch et al. by the ones derived from the present study does not bring about relevant changes of the results when the harmonic mean of two calibration factors, derived from serum cholesterol and triglycerides, is used, thus indicating that this method of calculation minimizes the effect of variation of the chemical composition of lipoproteins. The method is sufficiently reliable and reproducible for practical pruposes and is recommended as the standard method for the clinical laboratory.

Cholesterol↗
PubMed1978

Low-fat diet versus low-carbohydrate diet in the treatment of type IV hyperlipoproteinaemia.

The response to dietary management was studied in 24 hypertriglyceridaemic out-patients. Fourteen patients were kept on a diet low in fat and cholesterol and high in polyunsaturated fatty acids; 10 of these patients subsequently followed a period of low-carbohydrate diet. At the end of the first period a significant decrease of serum triglyceride, cholesterol and beta-lipoproteins was observed; after the second feeding period no substantial change of serum lipoprotein pattern occurred. Ten patients were given a low-carbohydrate diet that produced a significant fall of the levels of triglycerides and pre-beta-lipoproteins. Six of these subjects continued the experiment with the low-fat diet; during this period a further trend toward reduction of serum triglyceride, cholesterol and beta-lipoproteins was observed which, however, was not statistically significant. We conclude that serum triglyceride levels can be lowered both by a low-carbohydrate diet and by a low-fat diet, but the latter has the advantage of also producing a significant fall of serum cholesterol and beta-lipoproteins.

Adult↗